Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BIOCEPT INCBIOC · Entity 112149 | Director | December 09, 2021 | December 10, 2021 |
| Dermata Therapeutics, Inc.DRMA · Entity 8182 | Director | January 02, 2026 | January 06, 2026 |
| Histogen Inc.CNAT · Entity 112047 | Director | June 27, 2019 | July 01, 2019 |
| Oncternal Therapeutics, Inc.ONCT · Entity 89585 | Director | June 20, 2024 | June 24, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BIOCEPT INC
Report date December 09, 2021 · Filed December 10, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy LLC | 3,114 |
Reported balance
After 2021-12-09 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2021-12-09 · Sale · Disposed 363 · Balance 3,114 F1: The sales reported herein were made for tax planning purposes. |
| Common StockSEC Table I · non-derivative | IndirectBy trust | 101 |
Reported balance
After 2021-12-09 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2021-12-09 · Sale · Disposed 11 · Balance 101 F1: The sales reported herein were made for tax planning purposes. |
| Common StockSEC Table I · non-derivative | Direct | 796 |
Reported balance
After 2021-12-09 transaction · row 3
1 source rowRow 3 · 2021-12-09 · Sale · Disposed 71 · Balance 796 F1: The sales reported herein were made for tax planning purposes. |
Filing footnotes · ownership attribution and instrument terms
F1: The sales reported herein were made for tax planning purposes.
Dermata Therapeutics, Inc.
Report date January 02, 2026 · Filed January 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.18 · Expires 2036-01-01 | Direct | 2,500 |
Reported balance
After 2026-01-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-01-02 · Grant · Acquired 2,500 · Balance 2,500 F1: The shares underlying the option will vest in a series of twelve (12) successive substantially equal monthly installments, with the first installment vesting on the one month anniversary of the grant date and continuing to vest monthly thereafter, subject to Reporting Person's continuous service through each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares underlying the option will vest in a series of twelve (12) successive substantially equal monthly installments, with the first installment vesting on the one month anniversary of the grant date and continuing to vest monthly thereafter, subject to Reporting Person's continuous service through each such vesting date.
Histogen Inc.
Report date June 27, 2019 · Filed July 01, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.29 · Expires 2029-06-26 | Direct | 45,000 |
Reported balance
After 2019-06-27 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-06-27 · Grant · Acquired 45,000 · Balance 45,000 F1: The shares subject to this option become exercisable as the shares vest. The entire number of shares subject to this option becomes fully vested and exercisable on the first anniversary of the grant date, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to this option become exercisable as the shares vest. The entire number of shares subject to this option becomes fully vested and exercisable on the first anniversary of the grant date, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date.
Oncternal Therapeutics, Inc.
Report date June 20, 2024 · Filed June 24, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $8.10 · Expires 2034-06-20 | Direct | 3,300 |
Reported balance
After 2024-06-20 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-06-20 · Grant · Acquired 3,300 · Balance 3,300 F1: One-twelfth of the number of shares subject to the option vest and become exercisable in substantially equal installments on each monthly anniversary of the grant date, subject to the Reporting Person's continued service through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: One-twelfth of the number of shares subject to the option vest and become exercisable in substantially equal installments on each monthly anniversary of the grant date, subject to the Reporting Person's continued service through such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 30, 2019 Filed Jun 19, 2019 16:23 UTC | BIOCEPT INC BIOC · Entity 112149 | GrantEmployee Stock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $0.91 | $0.00 |
DisclosureSEC source: 0001209191-19-038017 · doc4.xml · derivative · entry 1 HALE DAVID F · CIK 0001024004 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2029-04-29 F1 · derivative.exercise_date: The option was granted on 4/30/19, but was contingent on shareholder approval of an increase in the shares issuable under the Issuer's 2013 Amended and Restated Equity Incentive Plan at the Issuer's annual meeting of stockholders held on 6/17/19, and therefore for purposes of Section 16 the option was not "acquired" until such stockholder approval was obtained. 25% of the shares subject to the option shall vest on the first annual anniversary of the Vesting Commencement Date (4/30/19) with the balance vesting in equal monthly installments thereafter until fully vested on 4/30/23 Read SEC document |
| June 29, 2018 Filed Jul 2, 2018 16:23 UTC | BIOCEPT INC BIOC · Entity 112149 | GrantEmployee Stock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $0.20 | $0.00 |
DisclosureSEC source: 0001209191-18-040329 · doc4.xml · derivative · entry 1 HALE DAVID F · CIK 0001024004 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2028-06-28 F1 · derivative.exercise_date: The shares subject to the option shall be 100% vested and exercisable on June 28, 2019. Read SEC document |
| June 21, 2018 Filed Jun 25, 2018 16:04 UTC | Histogen Inc. CNAT · Entity 112047 | GrantStock Option (Right to Buy) · Derivative | 45,000 | $0.00 Strike: $4.99 | $0.00 |
DisclosureSEC source: 0001209191-18-039395 · doc4.xml · derivative · entry 1 HALE DAVID F · CIK 0001024004 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 45,000 shares Expires 2028-06-20 F1 · derivative.exercise_date: The shares subject to this option become exercisable as the shares vest. The entire number of shares subject to this option becomes fully vested and exercisable on the first anniversary of the grant date, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date. Read SEC document |
| June 22, 2017 Filed Jun 26, 2017 16:12 UTC | Histogen Inc. CNAT · Entity 112047 | GrantStock Option (Right to Buy) · Derivative | 45,000 | $0.00 Strike: $4.96 | $0.00 |
DisclosureSEC source: 0001209191-17-041828 · doc4.xml · derivative · entry 1 HALE DAVID F · CIK 0001024004 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 45,000 shares Expires 2027-06-21 F1 · derivative.exercise_date: The shares subject to this option become exercisable as the shares vest. The entire number of shares subject to this option becomes fully vested and exercisable on the first anniversary of the grant date, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date. Read SEC document |
| May 31, 2017 Filed Jun 2, 2017 16:17 UTC | BIOCEPT INC BIOC · Entity 112149 | GrantEmployee Stock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $1.50 | $0.00 |
DisclosureSEC source: 0001209191-17-037227 · doc4.xml · derivative · entry 1 HALE DAVID F · CIK 0001024004 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2027-05-30 F1 · derivative.exercise_date: The shares subject to the option shall be 100% vested and exercisable on May 2, 2018. Read SEC document |
| March 31, 2017 Filed Apr 3, 2017 19:04 UTC | BIOCEPT INC BIOC · Entity 112149 | GrantEmployee Stock Option (right to buy) · Derivative | 4,166 | $0.00 Strike: $2.13 | $0.00 |
DisclosureSEC source: 0001209191-17-024282 · doc4.xml · derivative · entry 1 HALE DAVID F · CIK 0001024004 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,166 Underlying: Common Stock · 4,166 shares Expires 2027-03-30 F1 · derivative.exercise_date: The shares subject to the option shall be 100% vested and exercisable on June 28, 2017. Read SEC document |
| October 19, 2016 Filed Oct 21, 2016 17:04 UTC | BIOCEPT INC BIOC · Entity 112149 | PurchaseWarrant to Purchase Common Stock · Derivative | 90,909 | Not disclosed Strike: $1.10 | Not disclosed |
DisclosureSEC source: 0001209191-16-146605 · doc4.xml · derivative · entry 5 HALE DAVID F · CIK 0001024004 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By LLC Disclosed balance after: 90,909 Underlying: Common Stock · 90,909 shares Expires 2021-10-19 F4 · kind: Shares were purchased from the issuer in a unit offering, with each unit consisting of one share of Common Stock and one warrant to purchase one share of Common Stock for $1.10 per unit. F4 · price: Shares were purchased from the issuer in a unit offering, with each unit consisting of one share of Common Stock and one warrant to purchase one share of Common Stock for $1.10 per unit. Read SEC document |
| October 19, 2016 Filed Oct 21, 2016 17:04 UTC | BIOCEPT INC BIOC · Entity 112149 | PurchaseCommon Stock | 90,909 | $1.10 | $99,999.90 |
DisclosureSEC source: 0001209191-16-146605 · doc4.xml · nonDerivative · entry 3 HALE DAVID F · CIK 0001024004 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By LLC Disclosed balance after: 109,099 F4 · price: Shares were purchased from the issuer in a unit offering, with each unit consisting of one share of Common Stock and one warrant to purchase one share of Common Stock for $1.10 per unit. Read SEC document |
| June 16, 2016 Filed Oct 21, 2016 17:04 UTC | BIOCEPT INC BIOC · Entity 112149 | GiftCommon Stock | 13,334 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-16-146605 · doc4.xml · nonDerivative · entry 2 HALE DAVID F · CIK 0001024004 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By trust Disclosed balance after: 16,736 F1 · shares: As adjusted for the 1-for-3 reverse stock split effected September 27, 2016. F3 · balance_after: On September 27, 2016, the Issuer effected a 1-for-3 reverse stock split resulting in the reporting person's ownership of 33,468 fewer shares. Read SEC document |
| June 16, 2016 Filed Oct 21, 2016 17:04 UTC | BIOCEPT INC BIOC · Entity 112149 | GiftCommon Stock | 13,334 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-16-146605 · doc4.xml · nonDerivative · entry 1 HALE DAVID F · CIK 0001024004 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By LLC Disclosed balance after: 18,190 F1 · shares: As adjusted for the 1-for-3 reverse stock split effected September 27, 2016. F2 · balance_after: On September 27, 2016, the Issuer effected a 1-for-3 reverse stock split resulting in the reporting person's ownership of 36,380 fewer shares. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.